Skip to main content

Airway IL-1β associates with IL-5 production following dust mite allergen inhalation in humans



Preclinical studies implicate interleukin (IL)-1β as a key mediator of asthma and have shown the efficacy of IL-1 antagonism for treatment of allergic airway inflammation; human studies in this area are lacking.


Our aim was to study the relationship of airway IL-1β to features of acute allergen-induced asthma exacerbation in humans.


Dust mite-allergic adults with mild asthma underwent inhalation challenge with Dermatophagoides farinae. Fractional exhaled nitric oxide (FeNO), induced sputum and peripheral blood samples were obtained pre- and 24 h post-challenge. Spirometry was performed before and throughout the challenge at 10-min intervals, and allergen responsiveness was defined by a 20% fall in Forced Expiratory Volume in 1 s (FEV1). Sputum samples were analyzed for inflammatory cells, cytokines and chemokines. Multiple linear regression was employed to test the association between sputum IL-1β concentration and biomarkers of T helper type 2 (T2)-dominant inflammation.


Fourteen volunteers underwent inhaled allergen challenge. Allergen responsive volunteers showed a greater positive change in IL-1β in sputum following allergen challenge compared to non-responders. Higher pre-challenge sputum IL-1β was associated with greater increase in sputum IL-5 (p = 0.004), sputum eosinophils (p = 0.001) and blood IL-5 (p = 0.003) following allergen challenge. Allergen-induced sputum IL-1β production was significantly associated with sputum and blood IL-5 (p < 0.001 and p = 0.007, respectively), sputum IL-4 (p = 0.001), IL-13 (p = 0.026), eosinophils (p = 0.008) and FeNO (p = 0.03).


The positive association between production of IL-1β and biomarkers of T2 inflammation, particularly IL-5, in humans is consistent with work in animal models that demonstrates a link between IL-1β and the pathophysiology of allergic asthma. The role of IL-1β in human asthma warrants further study.


Increased recognition of complex asthma endotypes has prompted new efforts to understand the pathophysiology of severe and difficult-to-control asthma and to identify new treatment targets. Interleukin (IL)-1 is a crucial mediator of inflammation with a vast array of functions in the immune system, and preclinical data suggest it is an important mediator of asthma pathogenesis. In the lung, IL-1β induces transcription of pro-inflammatory genes that impact granulocyte recruitment, airway hyperreactivity, and mucous secretion [1, 2]. Humans with asthma showed greater IL-1β expression in bronchial epithelial cells and macrophages compared to non-asthmatics [3]. IL-1 antagonism was associated with reduction in airway hyperreactivity and eosinophil recruitment in a mouse model of T helper type 2 (T2)-predominant asthma [4] and reduction in the delayed response to intradermal allergen administration in humans [5], suggesting a role for IL-1β in the generation of allergic inflammation. Purported mechanisms for this activity include IL-1β induction of T2 cytokine production (e.g. IL-4, IL-5 and IL-13) by T helper cells and increased expression of cellular adhesion molecules necessary for eosinophil recruitment [6]. There is a paucity of human studies describing the relationship of airway IL-1β to features of allergic airway inflammation. We conducted inhaled allergen challenge in 14 adults with mild allergic asthma to investigate whether airway IL-1β is associated with airway and systemic T2 inflammation in humans.


Adults with mild intermittent asthma and sensitization to house dust mite (Dermatophagoides farinae, DF) underwent inhalation challenge with serial dilutions of DF extract (Stallergenes Greer®, Lenoir, NC) prepared in sterile saline using a protocol previously employed by our center [7]. Participants who experienced a ≥ 20% fall in forced expiratory volume in 1 s (FEV1) from baseline with inhaled allergen challenge were considered DF-responsive and observed for 10 h with spirometry performed at regular intervals. Spirometry, fractional exhaled nitric oxide (FeNO) measurements (NIOX Vero®, Circassia Pharmaceuticals, Inc, Morrisville, NC), blood and sputum samples were collected. Cytokines from sputum supernatants and serum were measured using multiplex immunoassays (Meso Scale Discovery®, Gaithersburg, MD). Within-group and between-group comparisons were made using Wilcoxon signed rank test and Mann–Whitney U test, respectively. Multiple linear regression was employed to test the association between sputum IL-1β concentration and inflammatory mediators of interest while adjusting for age and sex. Regression assumptions were reasonably satisfied, and no data transformations were necessary. Written informed consent was obtained from all participants, and the study was approved by the University of North Carolina Institutional Review Board. The study is listed on (NCT03049111).


Fourteen non-smoking volunteers with mild intermittent allergic asthma and sensitization to D. farinae underwent inhaled allergen challenge. The study population was 43% female with mean age of 27 (± 7, SD) years and BMI 27 (± 6) kg/m2. Eight (57%) volunteers were DF-responsive, and 6 participants were non-responsive. Pre-challenge sputum IL-1β concentrations were similar between DF-responsive and non-responsive participants. While sputum IL-1β did not significantly increase from pre-challenge levels in either group following allergen challenge (Fig. 1), the DF-responsive group showed a significantly greater positive change in sputum IL-1β following allergen challenge compared to non-responders [mean (SD) Δ sputum IL-1β = 102 (± 123.7) pg/mL (DF-responsive) v. -16.3 (± 31.1) pg/mL (non-responsive), p = 0.03].

Fig. 1
figure 1

Sputum IL-1β in D. farinae-responsive and non-responsive asthmatics. Fourteen participants underwent inhalation challenge with D. farinae, with sputum samples collected before and 24 h after challenge. Paired sputum samples were available for 11 of the participants, including 5 D. farinae-responsive and 6 non-responsive individuals. Pre and post-challenge sputum IL-1β concentrations were compared within groups using Wilcoxon signed rank test

In order to examine the relationship between sputum IL-1β and T2-dominant inflammation in response to allergen challenge, we performed regression analysis controlling for age and sex. Higher pre-challenge sputum IL-1β concentrations were associated with greater allergen-induced IL-5 in sputum and blood and sputum eosinophils (Fig. 2a–c). Greater allergen-induced rise in sputum IL-1β concentration was significantly associated with higher IL-5 in sputum and blood, higher sputum IL-4, IL-13 and eosinophils, and higher FeNO (Fig. 2d–i).

Fig. 2
figure 2

Sputum IL-1β concentration vs T2 inflammatory mediators. Multiple linear regression analysis was used to estimate the association of T2 inflammatory mediators to pre-challenge sputum IL-1β (ac) and to allergen-induced change in sputum IL-1β (di), after adjusting for age and sex. In each plot, the regression line is fit by fixing age as the mean age of all participants and sex as the proportion of males. β effect estimate; s.e. standard error


Airway inflammation in allergic asthma, the most common asthma endotype, is dominated by T2 cytokines including IL-4, IL-5 and IL-13. IL-5 is a critical mediator of eosinophil survival and recruitment to the airways in asthma. We detected a significant positive association between allergen-induced airway production of IL-1β and both airway and systemic production of IL-5 in adults with mild asthma. Additionally, we found that individuals with higher pre-challenge sputum IL-1β generated higher airway concentrations of IL-5, which could suggest that baseline IL-1β has a priming effect on T2-dominant airway inflammation. The impact may not be restricted to the airways, as we also showed that volunteers with higher pre-challenge sputum IL-1β displayed greater systemic production of IL-5 following allergen inhalation.

An imbalance of pro-inflammatory IL-1β and anti-inflammatory IL-1 receptor antagonist (IL-1RA) is a suggested mechanism for development of inflammatory diseases, including asthma [8]. Using a lipopolysaccharide (LPS) challenge model in humans, we previously reported that the synthetic IL-1 receptor antagonist, anakinra, reduced LPS-induced airway granulocyte recruitment and IL-1β concentrations compared to placebo [9]. The relationship detected between IL-1β and allergen-induced T2 biomarker responses in this study suggests anakinra could be studied for potential efficacy in allergic asthma as well.

The complexity and risks of inhaled allergen challenge procedures combined with restrictions put into place during the COVID-19 pandemic limited the size of our sample to a small number of otherwise healthy adults with mild intermittent allergic asthma. As such, the effects of allergen challenge on IL-1β and T2 cytokine production may not be reflective of the effects seen in patients with more severe forms of asthma.


Prior work in animal models suggests that IL-1 is an important mediator of T2-dominant asthma. Though our study design does not allow for assessment of causality, our findings do demonstrate a positive association between IL-1β and IL-5 production in humans with allergic asthma that warrants further study.

Availability of data and material

The datasets used and/or analyzed during the current study will be made available from the corresponding author on reasonable request.





Dermatophagoides farinae


Fractional exhaled nitric oxide


Forced expiratory volume in 1 s

T2 cells:

T helper type 2


Interleukin-1 receptor antagonist




  1. 1.

    Tsukagoshi H, Sakamoto T, Xu W, Barnes PJ, Chung KF. Effect of interleukin-1 beta on airway hyperresponsiveness and inflammation in sensitized and nonsensitized Brown-Norway rats. J Allergy Clin Immunol. 1994;93(2):464–9.

    CAS  Article  Google Scholar 

  2. 2.

    Chen Y, Garvin LM, Nickola TJ, Watson AM, Colberg-Poley AM, Rose MC. IL-1beta induction of MUC5AC gene expression is mediated by CREB and NF-kappaB and repressed by dexamethasone. Am J Physiol Lung Cell Mol Physiol. 2014;306(8):L797-807.

    CAS  Article  Google Scholar 

  3. 3.

    Sousa AR, Lane SJ, Nakhosteen JA, Lee TH, Poston RN. Expression of interleukin-1 beta (IL-1beta) and interleukin-1 receptor antagonist (IL-1ra) on asthmatic bronchial epithelium. Am J Respir Crit Care Med. 1996;154(4 Pt 1):1061–6.

    CAS  Article  Google Scholar 

  4. 4.

    Okada S, Inoue H, Yamauchi K, Iijima H, Ohkawara Y, Takishima T, et al. Potential role of interleukin-1 in allergen-induced late asthmatic reactions in guinea pigs: suppressive effect of interleukin-1 receptor antagonist on late asthmatic reaction. J Allergy Clin Immunol. 1995;95(6):1236–45.

    CAS  Article  Google Scholar 

  5. 5.

    Mullarkey MF, Leiferman KM, Peters MS, Caro I, Roux ER, Hanna RK, et al. Human cutaneous allergic late-phase response is inhibited by soluble IL-1 receptor. J Immunol. 1994;152(4):2033–41.

    CAS  PubMed  Google Scholar 

  6. 6.

    Lichtman AH, Chin J, Schmidt JA, Abbas AK. Role of interleukin 1 in the activation of T lymphocytes. Proc Natl Acad Sci USA. 1988;85(24):9699–703.

    CAS  Article  Google Scholar 

  7. 7.

    Bennett WD, Herbst M, Alexis NE, Zeman KL, Wu J, Hernandez ML, et al. Effect of inhaled dust mite allergen on regional particle deposition and mucociliary clearance in allergic asthmatics. Clin Exp Allergy. 2011;41(12):1719–28.

    CAS  Article  Google Scholar 

  8. 8.

    Gao P, Gibson PG, Baines KJ, Yang IA, Upham JW, Reynolds PN, et al. Anti-inflammatory deficiencies in neutrophilic asthma: reduced galectin-3 and IL-1RA/IL-1β. Respir Res. 2015;16:5.

    CAS  Article  Google Scholar 

  9. 9.

    Hernandez ML, Mills K, Almond M, Todoric K, Aleman MM, Zhang H, et al. IL-1 receptor antagonist reduces endotoxin-induced airway inflammation in healthy volunteers. J Allergy Clin Immunol. 2015;135(2):379–85.

    CAS  Article  Google Scholar 

Download references


We would like to thank Carole Robinette and Brian Ring for their assistance with inhaled allergen challenge procedures.


Research reported in this publication was entirely supported by the National Institutes of Health under Award Numbers NHLBI R01HL135235, NIAID T32AI007062, NCATS UL1TR002489 and KL2TR002490, NIEHS T32ES007018, NIEHS P42ES031007, and NIEHS P30ES010126. The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIH.

Author information




AJB, AS, and MLH made substantial contributions to the conception and design of the study. AJB, AS, MLH, KC and MA all contributed significantly to the acquisition of data. AJB, SAS, NB, HZ, and MLH contributed to the analysis and interpretation of the data. All authors read and approved the final manuscript.

Corresponding author

Correspondence to Allison J. Burbank.

Ethics declarations

Ethics approval and consent to participate

Written informed consent was obtained from all participants, and the study was approved by the University of North Carolina Institutional Review Board (#16-2131). The study is listed on (NCT03049111).

Consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit The Creative Commons Public Domain Dedication waiver ( applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Burbank, A.J., Schworer, S.A., Sood, A. et al. Airway IL-1β associates with IL-5 production following dust mite allergen inhalation in humans. Respir Res 22, 309 (2021).

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI:


  • Asthma
  • Allergic
  • Interleukin-1
  • T2-dominant asthma
  • Dust mite